Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events

Medicilon Events

Hot information:
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division| Medicilon FTE services & FFS services - flexible and efficient cooperation model| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon
May 21,2024
Medicilon honored with the 'Best Client Satisfaction Pharmaceutical CRO' at the 2024 VBEF."
On May 9th, the "2024 Top 100 Future Healthcare" series rankings were officially unveiled. Medicilon successfully made it onto the list and was awarded the "Best Client Satisfaction Pharmaceutical CRO" due to its outstanding market performance, human resources, knowledge resources, and essential partnership resources.
More
Medicilon honored with the 'Best Client Satisfaction Pharmaceutical CRO' at the 2024 VBEF."
May 16,2024
Medicilon congratulates - Treatable and Accessible! Adult and adolescent Type A and Type B influenza! AnDiCon Bio's pill cures influenza with the new drug Madoxanavir - Phase III successful research
Medicilon, as a partner of AnDiCon, provided formulation research services for the 'pediatric version' of the anti-influenza Class 1 Madoxanavir granules for influenza, assisting in its rapid advancement in preclinical research and development processes.
More
Medicilon congratulates - Treatable and Accessible! Adult and adolescent Type A and Type B influenza! AnDiCon Bio's pill cures influenza with the new drug Madoxanavir - Phase III successful research
May 16,2024
Empowering API Quality Enhancement! Medicilon Received the 'Best Collaboration Award' from Jingye Medicine & Chemical Co., Ltd
Recently, Medicilon is honored to have received a thank-you letter from Jingye Medicine & Chemical Co., Ltd (Jingye Medicine) and was awarded the "Best Collaboration Award".
More
Empowering API Quality Enhancement! Medicilon Received the 'Best Collaboration Award' from Jingye Medicine & Chemical Co., Ltd
May 16,2024
Winning for the third time in a row! Medicilon won the "Pharmaceutical Innovation Award - Top Ten Drug Innovation Service Institutions of the Year"
Medicilon USA Corp. (Medicilon) stood out with its cutting-edge innovative technology and excellent service capabilities, and won the "Pharmaceutical Innovation Award - Top Ten Drug Innovation Service Institutions of the Year".
More
Winning for the third time in a row! Medicilon won the "Pharmaceutical Innovation Award - Top Ten Drug Innovation Service Institutions of the Year"
May 07,2024
Technological Innovation, Authority Reaffirmed! Medicilon was awarded the "2023 Shanghai Science and Technology Little Giant Enterprise"
Recently, the Shanghai Science and Technology Commission officially issued the "Notice on the Announcement of the List of 2023 Shanghai Science and Technology Little Giants (Including Cultivation) Enterprises". Medicilon was recognized as one of the 2023 Shanghai Science and Technology Little Giants Company.
More
Technological Innovation, Authority Reaffirmed! Medicilon was awarded the "2023 Shanghai Science and Technology Little Giant Enterprise"
May 07,2024
World Cancer Day Focus: AACR Annual Meeting Leads Global New Cancer Drug Trends, Domestic Drugs Lead the Trend
At the AACR annual meeting, many top cancer research experts shared the latest scientific and medical research results. ​What is also eye-catching is that the Medicilon antibody drug conjugate (ADC) R&D service platform demonstrated its strong strength at this annual meeting.
More
World Cancer Day Focus: AACR Annual Meeting Leads Global New Cancer Drug Trends, Domestic Drugs Lead the Trend
May 07,2024
Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs
On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration. The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs.
More
Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs
Apr 10,2024
Medicilon (Chuansha) Inc. won the "Development Potential Award" of Chuansha New Town
Medicilon, relied on its outstanding performance and strong development momentum in the field of biopharmaceutical, won the "Development Potential Award" for the 2023 Chuansha New Town Economic Work Advanced Unit.
More
Medicilon (Chuansha) Inc. won the "Development Potential Award" of Chuansha New Town
Apr 10,2024
The 2024 Medicilon Innovative Drug Industry Ecological Collaboration Conference was a complete success
On March 18, the Medicilon Innovation Drug Industry Ecological Collaboration Conference was successfully held. At the conference, Medicilon starts of the globalization and the grand launch of two key technology service platforms.
More
The 2024 Medicilon Innovative Drug Industry Ecological Collaboration Conference was a complete success
Apr 10,2024
Medicilon once again ranked on the 2024 Shanghai Hard Core Technology Enterprises TOP100 List
Medicilon won the "2024 Shanghai Hard Core Technology Enterprises TOP100 List" with its hard-core technology and innovative technology service platform in the preclinical field of biopharmaceutical.
More
Medicilon once again ranked on the 2024 Shanghai Hard Core Technology Enterprises TOP100 List
Apr 10,2024
Medicilon and Innoforce Pharmaceuticals have reached a strategic collaboration to accelerate the innovative development of RNA, cell and gene therapy
On March 18, Medicilon and Innoforce Pharmaceuticals (Innoforce) reached a strategic collaboration, focusing on cutting-edge fields such as RNA, cell and gene therapy, and work together to open a new chapter in innovative drug research and development.
More
Medicilon and Innoforce Pharmaceuticals have reached a strategic collaboration to accelerate the innovative development of RNA, cell and gene therapy
Mar 19,2024
Medicilon Appoints Dr. Wenjie Li as Vice President of the CMC Unit to Expand our CRDMO Business
Medicilon announced the appointment of Dr. Wenjie Li as Vice President of the CMC Unit. With this appointment, Dr. Wenjie Li will continue to expand and strengthen Medicilon's services in the CRDMO field.
More
Medicilon Appoints Dr. Wenjie Li as Vice President of the CMC Unit to Expand our CRDMO Business